Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
new york blog main
13
×
new york top stories
national top stories
biotech
boston blog main
boston top stories
clinical trials
san francisco blog main
san francisco top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
amgen
indiana blog main
indiana top stories
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
fda
inclisiran
new york
regeneron pharmaceuticals
alnylam pharmaceuticals
cancer
cholesterol
europe blog main
europe top stories
merck
novartis
What
drug
13
×
fda
cholesterol
medicines
bio
lowering
market
medco
new
patients
pricing
roundup
approval
brings
cancer
ceo
data
immunotherapy
ipo
ipos
long
medicine
plan
therapeutics
twice
type
wave
week
aces
acquire
acquisitions
activity
advanced
advantages
agency
ago
agreed
aimmune
allergy
anathema
Language
unset
13
×
Current search:
unset
×
" new york blog main "
×
drug
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs